Profile data is unavailable for this security.
About the company
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
- Revenue in USD (TTM)2.42bn
- Net income in USD167.65m
- Incorporated1996
- Employees3.40k
- LocationBiomarin Pharmaceutical Inc105 Digital DrNOVATO 94949-8703United StatesUSA
- Phone+1 (415) 506-6700
- Fax+1 (415) 382-7889
- Websitehttps://www.biomarin.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therapeutics Corporation | 2.33bn | 984.80m | 11.03bn | 1.17k | 11.83 | 1.84 | 10.63 | 4.74 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Exact Sciences Corp | 2.50bn | -204.15m | 11.53bn | 6.50k | -- | 3.66 | 4,689.98 | 4.61 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Incyte Corp | 3.70bn | 597.60m | 11.60bn | 2.52k | 19.54 | 2.23 | 17.05 | 3.14 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.37bn | 20.00k | 26.02 | 3.43 | 15.57 | 3.00 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Medpace Holdings Inc | 1.96bn | 312.37m | 12.61bn | 5.90k | 41.48 | 18.74 | 37.12 | 6.43 | 9.82 | 9.82 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | -- | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Viatris Inc | 15.43bn | 54.70m | 13.49bn | 38.00k | 268.37 | 0.6665 | 4.83 | 0.8745 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 14.09bn | 1.40k | 57.62 | 6.19 | 51.99 | 7.47 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Biomarin Pharmaceutical Inc | 2.42bn | 167.65m | 17.47bn | 3.40k | 104.86 | 3.51 | 64.22 | 7.22 | 0.878 | 0.878 | 12.58 | 26.25 | 0.3661 | 0.5145 | 4.42 | 711,327.90 | 2.54 | 0.7773 | 2.93 | 0.8825 | 78.72 | 76.30 | 6.93 | 2.24 | 1.57 | -- | 0.18 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 1.83bn | -440.24m | 18.40bn | 2.10k | -- | -- | -- | 10.06 | -3.59 | -3.59 | 14.46 | -1.75 | 0.4957 | 2.85 | 8.43 | 870,615.30 | -11.94 | -26.56 | -15.61 | -32.77 | 83.02 | 83.66 | -24.08 | -94.26 | 2.99 | -2.11 | 1.28 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Holder | Shares | % Held |
---|---|---|
PRIMECAP Management Co.as of 31 Dec 2023 | 18.41m | 9.76% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 17.62m | 9.34% |
Dodge & Coxas of 31 Dec 2023 | 13.99m | 7.42% |
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 10.77m | 5.71% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 10.08m | 5.34% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.73m | 3.57% |
Barclays Bank Plc (Private Banking)as of 31 Dec 2023 | 5.16m | 2.74% |
Viking Global Investors LPas of 31 Dec 2023 | 4.89m | 2.59% |
Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 4.66m | 2.47% |
Avoro Capital Advisor LLCas of 31 Dec 2023 | 4.30m | 2.28% |